211 related articles for article (PubMed ID: 16267035)
1. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Dubé N; Bourdeau A; Heinonen KM; Cheng A; Loy AL; Tremblay ML
Cancer Res; 2005 Nov; 65(21):10088-95. PubMed ID: 16267035
[TBL] [Abstract][Full Text] [Related]
2. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
3. The role of protein tyrosine phosphatase 1B in Ras signaling.
Dubé N; Cheng A; Tremblay ML
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1834-9. PubMed ID: 14766979
[TBL] [Abstract][Full Text] [Related]
4. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Bentires-Alj M; Neel BG
Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
[TBL] [Abstract][Full Text] [Related]
6. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
7. Absence of CD5 dramatically reduces progression of pulmonary inflammatory lesions in SHP-1 protein-tyrosine phosphatase-deficient 'viable motheaten' mice.
Joliat MJ; Lang PA; Lyons BL; Burzenski L; Lynes MA; Yi T; Sundberg JP; Shultz LD
J Autoimmun; 2002 Mar; 18(2):105-17. PubMed ID: 11908943
[TBL] [Abstract][Full Text] [Related]
8. Genetic pathway to recurrent chromosome translocations in murine lymphoma involves V(D)J recombinase.
Vanasse GJ; Halbrook J; Thomas S; Burgess A; Hoekstra MF; Disteche CM; Willerford DM
J Clin Invest; 1999 Jun; 103(12):1669-75. PubMed ID: 10377173
[TBL] [Abstract][Full Text] [Related]
9. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
10. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors.
Slatter TL; Ganesan P; Holzhauer C; Mehta R; Rubio C; Williams G; Wilson M; Royds JA; Baird MA; Braithwaite AW
Cell Death Differ; 2010 Mar; 17(3):540-50. PubMed ID: 19779492
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Liu G; Trevillyan JM
Curr Opin Investig Drugs; 2002 Nov; 3(11):1608-16. PubMed ID: 12476961
[TBL] [Abstract][Full Text] [Related]
12. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Harley EA; Levens N
Curr Opin Investig Drugs; 2003 Oct; 4(10):1179-89. PubMed ID: 14649209
[TBL] [Abstract][Full Text] [Related]
13. Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
Pamidi A; Cardoso R; Hakem A; Matysiak-Zablocki E; Poonepalli A; Tamblyn L; Perez-Ordonez B; Hande MP; Sanchez O; Hakem R
Cancer Res; 2007 Sep; 67(18):8527-35. PubMed ID: 17875692
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes.
Lorenzo M; Fernández-Veledo S; Vila-Bedmar R; Garcia-Guerra L; De Alvaro C; Nieto-Vazquez I
J Anim Sci; 2008 Apr; 86(14 Suppl):E94-104. PubMed ID: 17940160
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Koren S; Fantus IG
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):621-40. PubMed ID: 18054739
[TBL] [Abstract][Full Text] [Related]
16. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.
Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D
Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689
[TBL] [Abstract][Full Text] [Related]
17. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice.
Ward JM; Tadesse-Heath L; Perkins SN; Chattopadhyay SK; Hursting SD; Morse HC
Lab Invest; 1999 Jan; 79(1):3-14. PubMed ID: 9952106
[TBL] [Abstract][Full Text] [Related]
18. Genetic interactions between the Wilms' tumor 1 gene and the p53 gene.
Menke AL; Clarke AR; Leitch A; Ijpenberg A; Williamson KA; Spraggon L; Harrison DJ; Hastie ND
Cancer Res; 2002 Nov; 62(22):6615-20. PubMed ID: 12438257
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a cell-based drug screening model for identifying down-regulators of Protein Tyrosine Phosphatase 1B expression.
Lian JH; Guo L; Hu WR; Wu GL; Ji W; Gong BQ
Exp Clin Endocrinol Diabetes; 2007 Jan; 115(1):24-8. PubMed ID: 17286230
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatases: the quest for negative regulators of insulin action.
Asante-Appiah E; Kennedy BP
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E663-70. PubMed ID: 12626322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
